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outcomes, the main fields covered by PROs (such as quality of life) in 
chronic diseases will be described. We will develop PRO measurement 
issues, notably psychometric properties and cultural adaptations, and 
also differences between generic and disease-specific instruments, 
with quality of life instruments as an example. Then we will define 
the use of PROs data in the field of adherence research, with their 
advantages and limitations compared with other sources of data. 
Last, the actual or potential impact of PROs will also be examined in 
terms of quality of care for daily medical practice and research issues.
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Summary: The new manifesto on clinical pharmacology (CP) empha-
sizes the importance of CP in delivery of health care, the role of CP 
that has not always been played the way and in the extent it was 
hoped for. In Croatia, CP has been recognized as a separate medical 
discipline/specialty since 1974. Since then, > 30 physicians have been 
trained in CP and work in various health care settings across country. 
Depending on the setting, they provide CP services, conduct research, 
and are involved in teaching. In some settings, clinical pharmacolo-
gists provide direct patient care, having a direct responsibility for 
patients, but more commonly provide a range of services to clinical 
colleagues and their patients as well as serve as consultants in regula-
tory and administrative bodies dealing with medications. Although 
specialists in CP, not all clinical pharmacologists involved in health 
care belong to established departments/units of CP. Differences in 
organizational models for delivering CP services to health care prob-
ably arise from not adequately defined functions of CP. The functions 
have been well defined in the new Manifesto but not well recognized 
by relevant bodies. We should not be ignoring the challenging future 
of CP in health care.
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Summary: UK health care is provided by a national health service 
(NHS), within which medicines are a major and growing cost. 
Concerns from patients, politicians, medical practitioners, and the 
press about “postcode” prescribing (marked regional differences 
in availability of newly licensed medicines) led to the creation of 
the Scottish Medicines Consortium (SMC). Run by NHS clini-
cians, SMC provides rapid advice on all new medicines, including 
new indications/formulations for existing therapies. A streamlined 
2-stage pharmacy and health economic, and then strategic, review 
of submissions from industry by SMC provides an objective review 
of the data and a wider societal view of need. A patient perspec-
tive is included. Comparative cost-effectiveness is assessed, prefer-
ably by using QALY ICERs, and advice given close to UK licensing 
(usually within 4 months). This early advice means that physicians 
are prepared to wait for the decision from SMC, and prescribing 
is relatively uncommon outside the guidance. Three outcomes are 
possible: (1) accept for general use; (2) accept with restriction (by 
specialist prescriber, or only for a subgroup within the license); or 
(3) do not recommend for use in Scotland. Appeals can be heard and 
resubmissions can be made if the evidence base changes. Around 
1000 submissions have now been made, including abbreviated sub-
missions for minor license changes, since 2002. Around two thirds of 
all medicines were accepted for use in NHS Scotland but many in a 
way more restrictive than the license. Around 50% of resubmissions 
are accepted. Evidence suggests SMC decisions are not influenced by 
budget impact (affordability) but are strongly influenced by whether 
the drug provides value for money to the NHS in Scotland. Accepted 
modifiers of decisions include orphan indications, end-of-life treat-
ment, bridging to a definitive treatment, and the development of 
licensed treatment where only an unlicensed preparation previously 
existed. Drug utilization data suggest that early advice influences 
prescribing patterns, in a positive way for approved drugs, and by 
lack of uptake (or reduction of existing prescribing) for those not rec-
ommended (with some exceptions). Benchmarking shows a high level 
of consistency with subsequent decisions from the National Institute 
for Health and Clinical Excellence (NICE), and the Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia. SMC has an ongo-
ing horizon scanning program, created a Scottish Management of 
Antimicrobial Resistance action Plan (ScotMARAP; 2008), and now 
runs a Patient Access Scheme to make high-cost drugs affordable 
to Scottish patients. An open and inclusive process, involving key 
stakeholders, can produce useful, rigorous, evidence-based advice 
to a health care system in a way that is acceptable to the NHS and to 
the pharmaceutical industry, and occurs sufficiently early after the 
launch of a new drug to inform and influence subsequent prescrib-
ing patterns.
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Summary: Despite being 1 of the most prevalent tropical diseases, for 
many years malaria was not a commercial priority for the pharma-
ceutical industry. However, in response to the emergence and spread 
of resistance to the available antimalarial drugs, there has been a 
renaissance in the discovery and development of new medicines to 
control the disease in the last few years. The persistent threat of 
resistance means that new molecules with novel mechanisms of action 
are continually required. Furthermore, the recent call for the elimi-
nation and eradication of malaria has prompted an extension of the 
stages of the life cycle of malaria parasites that should be targeted 
by new molecules. Recent advances in genome-based technologies 
and in vitro screening of whole parasites have broadened the range 
of therapeutic targets and are accelerating the development of a new 
generation of treatments for both malaria control and eradication.
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Summary: The purpose of regulatory toxicology is to evaluate all 
available information relevant to the toxicity of agents, which may 
be biological, chemical, or physical in nature, on behalf of govern-
mental or international organizations. The aim is to protect workers, 
consumers, the public generally, and the environment. Wherever pos-
sible, this is done through a process of quantitative or qualitative risk 
